Specifically, almost 75% of MM patients (19 out of 25) expressed high levels of PERK, and 30% (7 out of 25) expressed almost 20–80 fold higher PERK compared to the ES2 ovarian cancer cell line that was used as control (Figure 1B). The gene discussed is EIF2AK3; the disease is Miyoshi myopathy.